The global Anemia Therapy Market is expected to exceed US$ 10.0 billion in 2022. The market is expected to be worth US$ 14.9 billion by 2028, with sales increasing at a robust 6.9% CAGR.
According to a recent analysis by Future Market Insights, the condition as a result of one or more chronic diseases drives the majority of the demand for anemia therapy.
Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-8966
Chronic kidney disease (CKD), one of the non-communicable chronic diseases responsible for the epidemiological shift of emerging regions, is a major driver of the demand for anemia therapy. The market for anemia treatments is also being strongly influenced by the growing acceptance of combination therapy. Increasing use of vitamin and iron supplements, antibiotics, metal chelating agents, and erythropoietin stimulating medicines in combination therapy is recognized as a major driver propelling prospects of the anemia treatment industry in forthcoming years.
Vitamin Supplements Gain Significant Traction for Anemia Treatment
A surge in R&D investments is prominently improving scope of anemia treatment. Moreover, a rising number of pipeline drugs and promising potential of biosimilars will contribute to the demand for anemia treatment. However, high price point associated with biologics continues to mask their superior treatment efficacy over conventional medications.
More than 75% of anemia treatment market revenue is accounted by medications, of which, ESAs (erythropoietin stimulating agents) remain bestselling. Blood transfusion also cited as an important type of anemia treatment, contributing to the market growth. However, the demand for former is poised for a robust double-digit yearly growth in 2021 and ahead.
Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-8966
Lucrative emergence of ESAs and soaring consumption of other biosimilar medications are likely to introduce new investment opportunities in anemia treatment market. Extensive availability, accessibility, and economic price point of biosimilar drugs is strongly backed by an increasing number of FDA approvals. This according to FMI will significantly contribute in improvement of CKD, thereby bolstering the revenue of anemia treatment market. FDA recently issued an approval to a biosimilar drug by Pfizer for use in anemia treatment – Retacrit (epoetin alfa-epbx).
Over 55% of dietary supplements consumed as a part of anemia treatment are vitamin supplements. An increasing number of iron deficient patients will reportedly result in rapid demand growth of iron supplements in years to come, posing strong competition to that of vitamin supplements in the anemia treatment market. Currently, almost 60% of the medications and dietary supplements for anemia treatment is available at institutional pharmacies. The report also points to a gradually expanding share of retail pharmacies in the near future.
For more Report Customization, connect with us at@ https://www.futuremarketinsights.com/customization-available/rep-gb-8966
Just-under a third of the global demand for anemia treatment is raised by North American patients, whereas more than a third of the total demand is accounted collectively by East and South Asia. Europe is also cited as one of the key regional markets for anemia treatment providers.
Product-based Business Models Emerge as a Key Competitive Strategy
The consistent quest for therapeutically effective ESAs, dietary supplements, antibiotics, and other biologics to be used in anemia treatment continues to create attractive avenues in the R&D realm. Leading drug manufacturers are investing efforts in launching novel products and upgrading their existing consumable product portfolios. Amgen’s epoetin alpha has been a breakthrough product since its launch in the CKD treatment landscape and growing adoption continues to benefit the company.
Besides augmenting R&D investments, prominent players in anemia treatment market are also focusing on strategic agreements and partnerships – further paving the way for development of anemia treatment drugs. Emergence of partnership-based models in the competitive landscape of anemia treatment market is likely to reshape R&D structure in the anemia treatment market. The report prompts at major investment opportunities arising in open collaboration strategies. A number of drug manufacturers are also opting for partnerships with regional distribution leaders to form effective product-based distribution channels, particularly targeting developing regional markets.
𝑳𝒂𝒔𝒕 𝒇𝒆𝒘 𝒅𝒂𝒚𝒔 𝒕𝒐 𝒈𝒆𝒕 𝒓𝒆𝒑𝒐𝒓𝒕𝒔 𝒂𝒕 𝒅𝒊𝒔𝒄𝒐𝒖𝒏𝒕𝒆𝒅 𝒑𝒓𝒊𝒄𝒆𝒔, 𝒐𝒇𝒇𝒆𝒓 𝒆𝒙𝒑𝒊𝒓𝒆𝒔 𝒔𝒐𝒐𝒏!
𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭@ https://www.futuremarketinsights.com/checkout/8966
Anemia Treatment Market by Category
By Treatment:
- Medications
- Dietary Supplements
By Disease:
- Normocytic anemia
- Microcytic anemia
- Macrocytic anemia
By Distribution Channel:
- Institutional Pharmacies
- Retail Pharmacies
- Mail Order Pharmacies
Key Companies Profiled:
- Amgen Inc.
- Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
- Janssen Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- AMAG Pharmaceuticals
- Rockwell Medical
- Akebia Therapeutics
- Vifor Pharma Management Ltd.
Top Reports Related:
Preclinical Medical Device Testing Services Market
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs